Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 241

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 241
---
 December 31, 2024 or will become exercisable within 60 days after such date.         |

| (8) | Shares owed by Dr. de Vries are Ordinary Shares subject to outstanding stock options which are exercisable 
 at December 31, 2024 or will become exercisable within 60 days after such date.                            |

| (9) | Shares owed by all directors and senior management as a group include 57,518,875 Ordinary Shares subject                            
 to outstanding stock options, which are exercisable at December 31, 2024 or will become exercisable within 60 days after such date. |

As of December 31, 2024, approximately
0.01% of our outstanding Ordinary Shares was held by registered shareholders with addresses in the United Kingdom (excluding shares held
by the custodian under our depositary agreement with JPMorgan Chase Bank, N.A.), and we had 189 holders of record in the United Kingdom.
As of December 31, 2024, JPMorgan Chase Bank, N.A., as depositary for the Depositary Shares, held 6,392,362,427 Ordinary Shares, representing
95.6% of the issued share capital held at that date. As of December 31, 2024, we had five registered holders with an address in the United
States. The number of holders of record or registered holders in the United States or United Kingdom is not representative of the number
of beneficial holders or of the residence of beneficial holders.

Based on our share register,
we believe that we are not directly or indirectly controlled by another corporation or government, or by any other natural or legal persons.
There are no arrangements that may result in a change of control. Our major shareholders do not have different voting rights than other
holders of our Ordinary Shares.

To our knowledge, other than
due to the expiration of unexercised warrants held by our shareholders or as otherwise disclosed elsewhere in this prospectus, there has
been no significant change in the percentage ownership of our Ordinary Shares held by the principal shareholders listed above in the last
three years.

| 120 |

<div align='center'>DESCRIPTION OF SHARE CAPITAL</div>

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United State. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You